BPDF Aids Pharma Company with COVID-19 Vaccine Development
The BPDF is working with Vault Pharma, an emerging biotechnology company, on a vaccine that could treat patients who have the novel coronavirus and help prevent similar outbreaks in the future. The vaccine could be a complementary weapon to any initial vaccine for COVID-19 treatment. READ MORE
BPDF Producing Protein Therapeutic
for Coronavirus Patients
Working with a preclinical drug discovery company using its proprietary genetic technology platform, the BPDF is in early-stage production of a recombinant protein as a potential biotherapeutic for COVID-19 patients who may have few options for treatment.

The Biological Process Development Facility (BPDF) at the University of Nebraska offers biopharmaceutical process development designed for successful technology transfer from the bench to large-scale GMP manufacturing, and manufactures material suitable for non-clinical and clinical studies.

Specializing in recombinant peptides and proteins, the BPDF has produced GMP materials since 1998. During this time, processes for over 50 products including vaccines, other biotherapeutics, chemokines, and agricultural/industrial enzymes have been developed. BPDF fermentation processes focus on optimizing and controlling high cell-density fermentations of Pichia pastoris, Saccharomyces cerevisiae, and Escherichia coli for recombinant protein production. Current clients include government, industry, academic, and non-profit organizations.